The relationship between the daily dose, the plasma concentration of AD-5423 (blonanserin), and its plasma anti-dopamine (D2) and anti-serotonin (5-HT2A) activity, and the plasma serotonin/dopamine (S/D) ratio

Suzuki, Hideyuki; Morokawa, Y.; Gen, Keishi; Takagi, Hitoshi; Yamaguchi, Noboru; Tanaka, Chie; Aoba, A.

doi:10.1097/00004850-200305000-00039

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data are available from the manufacturer's prescribing information [8] or as an abstract; [22] some data were obtained from unpublished sources. Data are available from the manufacturer's prescribing information [8] or as an abstract; [22] some data were obtained from unpublished sources.…”

Section: Pharmacokinetic Propertiesmentioning

confidence: 99%

“…of vols tablet formulation (n = 18). [22] Blonanserin is highly plasma protein bound ( ‡99.7%) in vitro, [8] with albumin contributing the most to binding. [8] The plasma concentration of blonanserin has been shown to significantly (p < 0.01) correlate with the administered dose, as well as the dopamine-and serotonin-receptor antagonistic activity of the drug, in patients with schizophrenia (n = 11) [dosages not reported].…”

Section: Regimenmentioning

confidence: 99%

See 1 more Smart Citation

Blonanserin

2010

View full text Add to dashboard Cite

Oral blonanserin (Lonasen) is an atypical antipsychotic agent indicated for use in patients with schizophrenia in Japan and Korea. It is effective in the treatment of patients with schizophrenia, providing short- and long-term efficacy against both the positive and negative symptoms of the disorder in several randomized and noncomparative trials. Notably, in two randomized, double-blind trials of 8 weeks' duration, blonanserin was noninferior to haloperidol or risperidone for primary endpoints, although it appeared to be better than haloperidol in improving negative symptoms. Blonanserin is generally well tolerated and appears to have an acceptable profile in terms of bodyweight gain. Potential tolerability benefits of the drug in short-term trials included fewer extrapyramidal symptoms than haloperidol and fewer reports of prolactin level increases or hyperprolactinaemia than risperidone. Nevertheless, extrapyramidal symptoms and hyperprolactinaemia were among the most common adverse reactions associated with blonanserin in noncomparative long-term studies. Further prospective and long-term comparative studies are required in order to definitively position blonanserin with respect to other antipsychotic agents. In the meantime, available clinical data suggest that blonanserin is an effective and generally well tolerated option for the short-term treatment of schizophrenia and for those requiring longer-term therapy.

show abstract

Section: Pharmacokinetic Propertiesmentioning

confidence: 99%

Section: Regimenmentioning

confidence: 99%